KIN - Kindred Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.86
+0.03 (+0.28%)
As of 3:02PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close10.83
Open10.84
Bid10.87 x 800
Ask10.89 x 800
Day's Range10.82 - 11.35
52 Week Range8.05 - 15.75
Volume107,249
Avg. Volume183,841
Market Cap419.879M
Beta (3Y Monthly)-0.16
PE Ratio (TTM)N/A
EPS (TTM)-1.49
Earnings DateMar 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.80
Trade prices are not sourced from all markets
  • PR Newswire7 hours ago

    Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results

    Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 SAN FRANCISCO , Feb. 19, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...

  • PR Newswire6 days ago

    Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

    SAN FRANCISCO , Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...

  • PR Newswire7 days ago

    Kindred Group plc - Year end report January - December 2018 (Unaudited)

    Underlying EBITDA for the fourth quarter of 2018 was GBP 58.8 (74.5) million, and GBP 203.7 (185.0) million for the full year 2018. Profit before tax for the fourth quarter of 2018 amounted to GBP 45.0 (55.9) million, and GBP 149.5 (132.0) million for the full year 2018.

  • PR Newswire27 days ago

    Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN FRANCISCO, Jan. 23, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional shares of KindredBio's common stock, at $9.50 per share, less underwriting discounts and commissions. Barclays Capital Inc. and Stifel acted as joint book-running managers. A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.

  • PR Newswire28 days ago

    Kindred Biosciences Named Best Company in North America by Leading Industry Publication

    SAN FRANCISCO, Jan. 22, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio's transition to a commercial-stage firm in 2018 with the approval of Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

  • PR Newswirelast month

    Kindred Biosciences Announces Pricing of Public Offering

    SAN FRANCISCO, Jan. 18, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount of $40,042,500 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio.  KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 632,250 shares of its common stock on the same terms and conditions. Barclays Capital Inc. and Stifel are acting as joint book-running managers. A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.

  • PR Newswirelast month

    Kindred Biosciences Announces Proposed Public Offering of Common Stock

    SAN FRANCISCO, Jan. 17, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions.

  • PR Newswirelast month

    Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

    SAN FRANCISCO, Jan. 14, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats. In the study, which enrolled 23 cats with anemia, epoCat rapidly increased mean hematocrit (a measure of red blood cell count), with statistically significant improvement seen as early as Week 1 (p

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of KIN earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Kindred Biosciences Inc Earnings Call

  • PR Newswire3 months ago

    Kindred Biosciences Announces Third Quarter 2018 Financial Results

    SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its programs. For the third quarter 2018, KindredBio reported net product revenues of $0.6 million and a net loss of $13.0 million or $0.39 per share. "We are also pleased to have reported positive pilot effectiveness results for our lead canine atopic dermatitis biologic candidate last week. KindredBio recorded Mirataz® (mirtazapine transdermal ointment) net product revenues of $0.6 million in the third quarter.

  • PR Newswire4 months ago

    Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

    - Statistically significant reduction in pruritus versus placebo was achieved across all dose groups. - Canine atopic dermatitis is a large and growing market, and KindredBio has a broad portfolio of biologics in development to treat this condition. SAN FRANCISCO, Oct. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness study of KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 (IL-31), for the treatment of atopic dermatitis in dogs.

  • PR Newswire4 months ago

    Kindred Biosciences to Announce Third Quarter 2018 Financial Results

    Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, November 7, 2018 SAN FRANCISCO , Oct. 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...

  • Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President
    PR Newswire4 months ago

    Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President

    SAN FRANCISCO, Oct. 23, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio, has been elected to its Board of Directors and promoted to President. Since co-founding KindredBio in 2012, Ms. Bevers has assumed increasing levels of responsibility and has been instrumental in growing KindredBio into one of the world's leading veterinary biopharmaceutical companies. In her expanded role as President, Ms. Bevers will be responsible for all operational functions.

  • PR Newswire5 months ago

    Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

    SAN FRANCISCO , Sept. 17, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...

  • PR Newswire6 months ago

    Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

    SAN FRANCISCO , Aug. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of KIN earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Kindred Biosciences Inc Earnings Call

  • PR Newswire6 months ago

    Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference

    SAN FRANCISCO, Aug. 21, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4th in New York at the New York Marriott East Side. Denise Bevers, Co-Founder and Chief Operating Officer, will be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, key therapeutic programs in development, and upcoming milestones.

  • PR Newswire6 months ago

    Kindred Biosciences Announces Second Quarter 2018 Financial Results

    SAN FRANCISCO , Aug. 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial ...

  • PR Newswire7 months ago

    Kindred Biosciences to Announce Second Quarter 2018 Financial Results

    Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, August 9, 2018 SAN FRANCISCO , July 16, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...

  • PR Newswire7 months ago

    Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

    SAN FRANCISCO, July 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats is commercially available to veterinarians in the United States. Mirataz is the first and only transdermal medication for the management of weight loss in cats approved by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine. Unintended weight loss in cats is a serious and potentially fatal condition that represents the leading cause of visits to the veterinarian for cats.

  • PR Newswire8 months ago

    Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

    SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced the underwriters have exercised in full their option to purchase an additional 694,736 shares of KindredBio's common stock at $9.50 per share, less underwriting discounts and commissions. KindredBio also announced that it has closed its public offering of 5,326,314 shares of common stock at a public offering price of $9.50 per share, which included the sale of the shares pursuant to the option to purchase additional shares, for a total offering amount of approximately $50.6 million before deducting underwriting discounts and commissions and offering expenses payable by KindredBio. Cantor Fitzgerald & Co. acted as sole book-running manager for the offering.  B. Riley FBR acted as co-manager.  A.G.P. / Alliance Global Partners, H.C. Wainwright & Co., Ladenburg Thalmann, and Lake Street Capital Markets LLC provided financial advisory services.

  • PR Newswire8 months ago

    Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program

    SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its "at-the-market" equity offering program (the "ATM Facility") with B. Riley FBR, Inc. and Oppenheimer & Co. Inc. as sales agents. "With the recent successful offering, KindredBio is now well capitalized and we do not anticipate requiring additional funding to achieve our current corporate and development objectives," stated Richard Chin, CEO of KindredBio.

  • Bringing world class medication to animals
    Yahoo Finance Video25 days ago

    Bringing world class medication to animals

    KindredBio is a company focused on bringing ground-breaking human products and innovative new technologies to veterinary medicine. Yahoo Finance's Adam Shapiro and Brian Sozzi discuss with company founder & CEO, Richard Chin, along with its founder and president, Denise Bevers.